About Kanabo

The Company

Kanabo is creating a new standard in the medical cannabis industry by improving the well-being of millions around the world. We focus on the distribution of Cannabis-derived products for medical patients, and non-THC products for CBD consumers. We have conducted extensive R&D in order to develop high-quality Cannabis extract formulas, innovative medical-grade vaporizers, and various non-smoking consumption solutions – making use easy and accessible for anyone in need of treatment. Clinical and validation activities, including safety and efficiency tests, are conducted in Israel – an established leader in the Cannabis industry.

The company is selling initial products in Europe already, and is ready to scale up to meet market demands and projected sales and revenues.

History of Cannabis in Israel

Israel is one of the leading countries in the world in cannabinoid research, and the reason for that is because we started when nobody else was doing it Raphael Mechoulam

Israel is an established leader in Cannabis research and innovation. Israeli scientists became the first to isolate and identify the active compounds of cannabis in the 1960s, and later identified the endocannabinoid system in the 1990s.

After approving cannabis for medical use in the 1990s, the Israeli Ministry of Health initiated their state regulated medical cannabis program in 2007 and licensed farms to produce medical cannabis for patients suffering from approved conditions. In 2011, the country recognized the therapeutic use of Cannabis. Today, there are over 46,000 approved patients in Israel with 8 licensed farms producing and distributing medical cannabis to patients. Those numbers are expected to rise, with the Ministry receiving a reported 300 applications per day.

When compared to the German medicinal Cannabis market, which only began issuing prescriptions in 2007, there are already comparable numbers. While there are no centralized patient numbers in Germany, estimates from 2018 suggest that there are already 60,000 patients consuming cannabis in the country. While the local market remains small, over 100 cannabis companies are currently active in Israel, and some analysts believe the recent move to allow cannabis exports from Israel may unlock a US$4B market. Between 2013-2017, cannabis related Israeli startups have raised $76.4 million in equity. Israel is recognized as a global leader in cannabis research, cannabis healthcare, product innovation, and technology.

History of Kanabo

Kanabo was born out of Founder and CEO Avihu Tamir’s personal experience working with medical Cannabis patients in Israel – a pioneering leader in the field of medical Cannabis. Israel is the first country to allow medical and scientific research of Cannabis, and the first country to establish a national medical Cannabis program for patients. In Israel, a patient prescribed Cannabis is often directed to smoke their prescription – or even mix it with tobacco to ‘make it burn better.’ Concerned about the long-term health effects of smoking, Avihu began exploring and providing healthier options for Israeli medical cannabis patients and others, with a focus on vaporization.

At the time, Avihu found that there were no medical vaporizers for Cannabis patients available in Israel or around the world. He set out to change this, and became the first importer of vaporizers in Israel. He founded the vaporizer import company Teva Nature Ltd., which is still the leading importer and provider of vaporizers to the Israeli market. Avihu has now worked with hundreds of patients over the last several years to provide access to vaporizer devices, training, consultation, and support for patients using medical Cannabis. After learning the market and the different available alternatives, Avihu understood that there was a need for the development of medical grade vaporizer solutions.


Kanabo’s leadership team is made up of experienced medical industry professionals in a variety of fields shaping the medical Cannabis industry, including biopharmaceuticals, pharmaceutical R&D, Drug Delivery Systems (DDS), clinical research, medical patents, vaporizer technology, botanical extracts, and more. Featured members of Kanabo’s leadership team are included below.

Executive Team

David Tsur

Chairman, Non-Executive Director

Mr. Tsur is the Co-founder of Kamada Ltd, a public company listed on both the NASDAQ and Tel-Aviv Stock Exchange. He has served as its Chief Executive Officer and on its board of directors since the company’s inception in 1990, until July 2015. Currently he serves as Kamada’s Active Deputy Chairman of the Board.
Prior to co-founding Kamada, Mr. Tsur was the Chief Executive Officer of Arad Systems and RAD Chemicals Inc. He has also held various positions in the Israeli Ministry of Economy (formerly named the Ministry of Industry and Trade), including Chief Economist and Commercial Attaché in Argentina and Iran.
Mr. Tsur holds a BA degree in Economics and International Relations and a MBA in Business Management from the Hebrew University of Jerusalem.

Gil Efron

Non-Executive Director

Mr. Efron is serving as President and Chief Financial Officer of NASDAQ and TASE dual-listed Purple Biotech Ltd., a clinical-stage company (PPBT) since June 2021, having previously held the position of Deputy Chief Executive Officer and Chief Financial Officer from October 2018. Prior to his current tenure at Purple Biotech, Gil served as Deputy CEO and CFO of Kamada Ltd., a NASDAQ and TASE dual-listed plasma-derived protein therapeutics company between 2011-2017.

Mr. Efron holds a B.A. degree in Economics and Accounting and an M.A. degree in Business Administration from the Hebrew University of Jerusalem and was granted a certified public accountant’s license in Israel.

Avihu Tamir

CEO, Executive Director

Mr. Tamir is a cannabis entrepreneur with seven years hands-on experience in multiple cannabis ventures and has vast experience in consulting for international cannabis projects. Mr. Tamir began his career and built his reputation as a senior strategy consultant at Accenture. He is also the founder of Teva Nature, the leading vaporizer company in Israel.
Mr. Tamir founded Kanabo Research in 2016 and since then has served as its CEO of the company. His expertise includes biotechnology, new agriculture and agro-tech, and other breakthrough technologies in the dynamic field of Medical Cannabis.
Mr. Tamir holds a B.A. in Finance and Risk Management (Magna Cum Laude), and a M.A. in Political Science (Magna Cum Laude) from the IDC Herzliya.

Andy Morrison

Non-Executive Director

Formerly Chairman of Spinnaker Opportunities, Mr Morrison has focused on managing and developing junior public companies, largely in the energy sector including Xtract Energy Plc, Silvermere Energy Plc and Zeta Petroleum Plc, an ASX quoted firm with operations in Romania.

He began his career at Shell in oil products and in 1999, joined BG Group Plc as a New Ventures Director. Subsequently he held senior New Business Development roles for the industrial gases group BOC Group Plc until its acquisition in 2007. Mr Morrison has a BSc in Chemical Engineering and Fuel Technology from the University of Sheffield and a Diploma in Company Direction from the Institute of Directors.

Dr. Daniel Poulter

Non-Executive Director

Dr Poulter is a former U.K. health minister with a detailed knowledge of the medicines and drugs regulatory framework in the UK. and across Europe.

He studied law at Bristol University and has a degree in medicine from Guy’s, King’s and St Thomas’ School of Medicine. Before retraining as an NHS psychiatrist, Dr Poulter previously worked as a hospital doctor specializing primarily in women’s health. He continues to practice medicine as an NHS hospital doctor on a part-time basis.

Dr Poulter’s medical experience and extensive knowledge of both healthcare policy and regulation makes him well placed to support the company’s approach to establishing medicinal cannabis markets.


Assaf Vardimon


Mr. Vardimon brings over 20 years of finance experience in the High-Tech and real-estate sectors. In the past four years he served as partner and CFO in Brooks-Keret, a leading company specialized in providing financial management for startups and High-Tech companies.

Prior to Brooks-Keret Mr. Vardimon worked in Kimberly Enterprises N.V. (KBE: AIM Stock Exchange), a leading real-estate group that operates in East Europe, and served as their CFO. Earlier in his career, he spent three years at the accounting firm KPMG. He is a qualified CPA and holds an MBA in Finance and a BA in Accounting and Management from the Academic College of Management Israel.

Michal Ben Moshe

General Manager

Mrs. Ben Moshe has 20 years of leadership experience in a variety of organizations and industries. In her last position, she served as the Senior Director of Finance & Commercial Affairs at S.L.E Ltd., one of the leading providers of logistics and operations in the healthcare field in Israel and a part of Teva Group (the largest generic pharmaceutical manufacturer worldwide). Mrs. Ben Moshe has in-depth knowledge of commercial activities, finance, and operations.

She has a proven track record in development and growth implementation strategies, and further achievements include strengthening relationships with global stakeholders and positioning S.L.E on an international scale.

Mrs. Ben Mosheis Certified Public Accountant (CPA) and holds B.A. in Accounting and Economics from Tel-Aviv University.

Yonatan Hillinger

RA Director

Mr. Hillinger has over 10 years of experience in establishing Regulatory Affairs and Quality Assurance Systems, both in the Pharmaceutical and the Medical Device industries. After completing a BSc in Biochemistry and MSc in Clinical Biochemistry, he began his career at Johnson & Johnson, working alongside many of the global regulatory authorities In Asia, Europe and America (north and south).
Mr. Hillinger established the RA department at Syqe Medical and led the certification process of ISO 13485, the CE Mark and MDSAP for a medicinal Cannabis inhaler.
In his last position as QA/RA Manager at XRHealth, Mr. Hillinger established the QMS, receiving ISO 13485 and ISO 27001 certifications with successful registration in IL, EU (MDR), AU and US.

Tal Lupo

R&D Director

Mr. Lupo is an experienced cannabis scientist and product development expert. He thrives on taking projects from concept to market. In addition, he is a professional scientific educator and a content writer. He holds several patents and peer-reviewed articles.

Mr. Lupo began his professional path as the Head of Lab at Syqe Medical and Head of Product Development at a Cannabinoid Nano Technology company.
Mr. Lupo earned his BSc studies in Biotechnology from Ruppin Academic Center and MSc in molecular biology and genetics from the Weizmann Institute of Science.

Joshua Berman

Director of Global BD & Relationships

Mr. Berman has been an executive in the cannabis industry since 2014. As the head of business development at iCAN Israel-Cannabis and the director at CannaTech, his focus was innovation across the global cannabis supply chain, focused on bringing together entrepreneurs, scientists, and investors to its premier cannabis events across the globe.

Originally from Seattle and now based in Israel, Mr. Berman brings his global experience, partners, and know-how to the Kanabo platform.

Eilon Bdil

VP of Production

  • Medical Cannabis Cultivation & Production
  • Over 10 years experience managing a licensed medical cannabis cultivation and production facility in Southern Israel, including crop and business management.
  • Non-Executive Director of Hadiklaim, Date Grower’s Cooperative. Hadiklaim exports to more than 30 countries and is the biggest producer of Medjool dates in the world.
  • Former CEO of Kibbutz Elipaz and Local Council Member.

Ophir Shimshi, Adv.

Director of Business Operations

  • Co-Founder and partner in a private law firm, Hoyzman, Weinbaum, Shimshi.
  • Co-Founder and partner in a specialized entrepreneurs group, mainly dealing in real estate transactions and development and in renewable energy projects, both in Europe and in Israel.
  • Former senior lawyer at Jacob Cohen & Co Law Office, specializing in corporate law, commercial law, real estate – planning and construction.

David Sack


  • Marketing; Branding; Business Development
  • David is an execution veteran with extensive marketing, branding and business development experience. David has been helping startups turn into enterprises for over 20 years. David managed global operations and marketing in 100+ staff companies internationally, and today leads Kanabo’s Marketing.


Yossi Aldar

Medical Device Advisor

  • Executive Management; Medical Devices
  • Experienced executive manager specializing in biomedical and medical device companies. Diverse experience includes work as CEO of Syqe Medical, creators of the first medical grade cannabis inhaler. Served has Co-Founder and CEO of SteadyMed Therapeutics, Inc. (NASDAQ: STDY), Managing Director of VersaMed) acquired by GE Healthcare), and Founder and CEO of Flight Medical (TASE: FLGM).

Nachshon Knoller, M.D.

Clinical & Medical Advisor

  • Medicine, Clinical trials, Pharmaceutical Research
  • Leading spinal neurosurgeon of Israel, currently Director of the Department of Neurosurgery at Sheba Medical Center in Tel-Hashomer, Israel. Serves as a Member of the Scientific Advisory Board of Proneuron Biotechnologies, Inc. and has served as an Advisory Board Member of Mazor Surgical Robotics Ltd. Research activities include emerging medication treatments and cell therapy (macrophages) for traumatic brain and spinal injuries.

Doron Friedman, Ph.D.

Scientific Advisor

  • Formulations; Patents & IP
  • Specialist in pharmaceutical R&D with over 25 years experience as a biomedical entrepreneur and executive who holds over 80 patents, making him the most prolific patent inventor in Israel. Inventor of Bausch and Lomb’s Lotemax eye drops; served as Director of Pharmaceutical Development at Pharmos Corp, Chief Technology officer of Foamix Ltd; and pharmaceutical development consultant.